SI2885007T1 - Postopki in kompozicije glikokonjugacij - Google Patents

Postopki in kompozicije glikokonjugacij

Info

Publication number
SI2885007T1
SI2885007T1 SI201331242T SI201331242T SI2885007T1 SI 2885007 T1 SI2885007 T1 SI 2885007T1 SI 201331242 T SI201331242 T SI 201331242T SI 201331242 T SI201331242 T SI 201331242T SI 2885007 T1 SI2885007 T1 SI 2885007T1
Authority
SI
Slovenia
Prior art keywords
glycoconjugation
compositions
processes
glycoconjugation processes
Prior art date
Application number
SI201331242T
Other languages
English (en)
Slovenian (sl)
Inventor
Jianxin Gu
Jin-Hwan Kim
A. Krishna Prasad
Yu-Ying Yang
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SI2885007T1 publication Critical patent/SI2885007T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SI201331242T 2012-08-16 2013-08-12 Postopki in kompozicije glikokonjugacij SI2885007T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261684043P 2012-08-16 2012-08-16
EP13779365.9A EP2885007B1 (en) 2012-08-16 2013-08-12 Glycoconjugation processes and compositions
PCT/IB2013/056597 WO2014027302A1 (en) 2012-08-16 2013-08-12 Glycoconjugation processes and compositions

Publications (1)

Publication Number Publication Date
SI2885007T1 true SI2885007T1 (sl) 2018-12-31

Family

ID=49385307

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201331242T SI2885007T1 (sl) 2012-08-16 2013-08-12 Postopki in kompozicije glikokonjugacij
SI201331739T SI3421051T1 (sl) 2012-08-16 2013-08-12 Postopki in kompozicije glikokonjugacij

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201331739T SI3421051T1 (sl) 2012-08-16 2013-08-12 Postopki in kompozicije glikokonjugacij

Country Status (32)

Country Link
US (6) US9517274B2 (en:Method)
EP (2) EP2885007B1 (en:Method)
JP (1) JP6291495B2 (en:Method)
KR (1) KR101742406B1 (en:Method)
CN (1) CN104661684B (en:Method)
AR (1) AR092368A1 (en:Method)
AU (1) AU2013303826B2 (en:Method)
BR (1) BR112015003227B1 (en:Method)
CA (1) CA2881420C (en:Method)
DK (2) DK2885007T3 (en:Method)
ES (2) ES2700824T3 (en:Method)
FI (1) FIC20220032I1 (en:Method)
FR (1) FR22C1037I2 (en:Method)
HU (3) HUE049531T2 (en:Method)
IL (1) IL237066B (en:Method)
IN (1) IN2015DN00694A (en:Method)
LU (1) LUC00273I2 (en:Method)
MX (1) MX363511B (en:Method)
MY (1) MY167579A (en:Method)
NL (1) NL301188I2 (en:Method)
NO (1) NO2022034I1 (en:Method)
NZ (1) NZ704490A (en:Method)
PE (1) PE20150464A1 (en:Method)
PH (1) PH12015500243B1 (en:Method)
PL (2) PL2885007T3 (en:Method)
PT (2) PT3421051T (en:Method)
RU (2) RU2645071C2 (en:Method)
SA (1) SA515360035B1 (en:Method)
SG (1) SG11201500566XA (en:Method)
SI (2) SI2885007T1 (en:Method)
TW (1) TWI480049B (en:Method)
WO (1) WO2014027302A1 (en:Method)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6291495B2 (ja) 2012-08-16 2018-03-14 ファイザー・インク 糖鎖付加プロセスおよび組成物
CN112336854B (zh) * 2014-01-21 2024-11-26 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
DK3096783T3 (da) 2014-01-21 2021-08-02 Pfizer Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf
NZ760783A (en) * 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015121783A1 (en) * 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
EP3915999A1 (en) 2014-03-13 2021-12-01 Universität Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
HRP20230416T1 (hr) 2015-01-15 2023-07-07 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
TWI807252B (zh) * 2015-05-04 2023-07-01 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
CN107847571A (zh) * 2015-06-08 2018-03-27 印度血清研究所私人有限公司 用于改善多糖‑蛋白质缀合物及其获得的多价疫苗配制剂的吸附的方法
TWI756893B (zh) * 2015-07-21 2022-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
CN108026134A (zh) * 2015-09-16 2018-05-11 巴塞尔大学 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
US11241489B2 (en) 2016-08-05 2022-02-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11224652B2 (en) 2016-08-05 2022-01-18 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
MA47223A (fr) 2016-12-30 2019-11-06 Sutrovax Inc Conjugués polypeptide-antigène avec des acides aminés non naturels
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
KR102459629B1 (ko) 2017-01-20 2022-10-28 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
CA3066911C (en) * 2017-06-10 2022-05-24 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3074714A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
MX2020002559A (es) 2017-09-07 2020-07-13 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
BR112020014978A2 (pt) 2018-02-05 2020-12-22 Sanofi Pasteur, Inc. Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
CN111757753B (zh) 2018-02-05 2024-08-20 赛诺菲巴斯德有限公司 多价肺炎球菌多糖-蛋白质缀合物组合物
CN111615400B (zh) * 2018-03-23 2025-05-02 科纳克斯资本 作为治疗工具的精确糖缀合物
CA3096358A1 (en) 2018-04-18 2019-10-24 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharide and immunogenic conjugate thereof
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN111024832B (zh) * 2019-10-29 2022-05-03 北京成大天和生物科技有限公司 多糖结合疫苗中残余NaCNBH3的离子色谱检测方法
US20230000966A1 (en) 2019-11-01 2023-01-05 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
PE20230170A1 (es) 2020-02-23 2023-02-01 Pfizer Composiciones de escherichia coli y sus metodos
EP4192499A4 (en) 2020-08-10 2024-09-25 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
UY39428A (es) 2020-09-17 2022-03-31 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
KR20230096033A (ko) 2020-10-27 2023-06-29 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그의 방법
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
EP4333879A1 (en) 2021-05-03 2024-03-13 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
CA3221074A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
AU2023385908A1 (en) 2022-11-22 2025-05-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250113501A (ko) 2022-12-01 2025-07-25 화이자 인코포레이티드 폐렴구균 접합체 백신 제형
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US578573A (en) 1897-03-09 Brake-actuating mechanism
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5769047A (en) 1991-12-23 1998-06-23 Zoche; Michael Engine with oil separator
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CA2293739A1 (en) 1997-06-12 1998-12-17 Shin-Etsu Bio, Inc. Production of non-native bacterial exopolysaccharide in a recombinant bacterial host
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
EP2332581B1 (en) * 2001-01-23 2015-07-01 Sanofi Pasteur Inc. Tri- or tetravalent meningococcal polysaccharide-CRM197 conjugate vaccine
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
CA2449670A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
CN1394867A (zh) * 2001-07-06 2003-02-05 中国科学院生态环境研究中心 可作药物的寡糖和其制备方法及含该寡糖的药物组合物
AU2003277139A1 (en) * 2002-10-03 2004-04-23 Wyeth Holdings Corporation Process for preparing monoprotected diols from symmetric diols
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CN1942478A (zh) * 2004-04-14 2007-04-04 惠氏公司 用于制备与二羧酸的纳巴霉素42－酯和fk－506 32－酯的方法，用于纳巴霉素配合物的前体和抗体
US7910753B2 (en) * 2004-09-10 2011-03-22 Anaspec Incorporated Cyanine dyes and their applications as luminescence quenching compounds
KR102220506B1 (ko) 2005-04-08 2021-03-02 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PT1973564T (pt) * 2005-12-22 2017-01-24 Glaxosmithkline Biologicals Sa Vacina compreendendo conjugados polissacarídicos capsulares de streptococcus pneumoniae
TW200806685A (en) * 2006-02-21 2008-02-01 Wyeth Corp Processes for the convergent synthesis of calicheamicin derivatives
BRPI0708562A2 (pt) * 2006-03-07 2011-06-07 Wyeth Corp processos para preparar conjugados de polietileno glicor de macrolìdeos imunossupressores, um macrolìdeo imunossupressor peguilado, uma rapamicina peguilada, um everolimus peguilado, um cci-779 peguilado e um tacrolimus peguilado, e, produto
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
DE102006026436A1 (de) * 2006-06-07 2007-12-13 Continental Aktiengesellschaft Verfahren und Messfahrzeug zur Ermittlung objektiver Reifeneigenschaften auf einer Fahrbahnoberfläche
WO2008157590A1 (en) * 2007-06-20 2008-12-24 Baxter International Inc. Modified polysaccharides for conjugate vaccines
RU2378015C2 (ru) * 2008-04-02 2010-01-10 Равшан Иноятович Атауллаханов Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности
US9125951B2 (en) * 2009-06-22 2015-09-08 Wyeth Llc Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
CA2766614C (en) * 2009-07-03 2018-06-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
HUE037733T2 (hu) * 2009-11-24 2018-09-28 Grifols Therapeutics Inc Liofilizálási eljárások, készítmények, és készletek
CN103391714A (zh) * 2010-12-10 2013-11-13 默沙东公司 减轻搅动引起的免疫原性组合物聚集的新制剂
EP2755691B1 (en) * 2011-09-07 2018-08-22 Prolynx LLC Hydrogels with biodegradable crosslinking
JP6291495B2 (ja) * 2012-08-16 2018-03-14 ファイザー・インク 糖鎖付加プロセスおよび組成物
NZ760783A (en) 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015121783A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates

Also Published As

Publication number Publication date
MX363511B (es) 2019-03-26
WO2014027302A1 (en) 2014-02-20
AU2013303826B2 (en) 2017-06-29
US20180221467A1 (en) 2018-08-09
JP2015524839A (ja) 2015-08-27
PT2885007T (pt) 2018-12-10
PH12015500243B1 (en) 2019-05-31
CA2881420C (en) 2016-11-15
RU2015103017A (ru) 2016-10-10
DK3421051T3 (da) 2020-06-22
PL3421051T3 (pl) 2020-10-05
FR22C1037I2 (fr) 2023-05-26
EP2885007B1 (en) 2018-10-10
HK1210021A1 (en) 2016-04-15
HUE041381T2 (hu) 2019-05-28
US9950054B2 (en) 2018-04-24
CA2881420A1 (en) 2014-02-20
CN104661684A (zh) 2015-05-27
SG11201500566XA (en) 2015-04-29
PH12015500243A1 (en) 2015-03-30
TWI480049B (zh) 2015-04-11
US10583187B2 (en) 2020-03-10
FIC20220032I1 (fi) 2022-08-05
KR101742406B1 (ko) 2017-05-31
NL301188I2 (nl) 2024-05-15
BR112015003227A2 (pt) 2017-07-04
KR20150041139A (ko) 2015-04-15
AU2013303826A1 (en) 2015-02-12
ES2800479T3 (es) 2020-12-30
US20170224804A1 (en) 2017-08-10
LUC00273I2 (en:Method) 2025-05-12
US11110160B2 (en) 2021-09-07
US20200246448A1 (en) 2020-08-06
RU2016136630A3 (en:Method) 2019-12-30
ES2700824T3 (es) 2019-02-19
RU2645071C2 (ru) 2018-02-15
SA515360035B1 (ar) 2015-09-15
DK2885007T3 (en) 2018-12-03
RU2016136630A (ru) 2018-12-11
IL237066B (en) 2019-03-31
SI3421051T1 (sl) 2020-08-31
AR092368A1 (es) 2015-04-15
MX2015001992A (es) 2015-10-05
PE20150464A1 (es) 2015-04-25
US9517274B2 (en) 2016-12-13
US20150216996A1 (en) 2015-08-06
EP2885007A1 (en) 2015-06-24
NZ704490A (en) 2017-07-28
RU2724840C2 (ru) 2020-06-25
US20230355735A1 (en) 2023-11-09
HUE049531T2 (hu) 2020-10-28
FR22C1037I1 (fr) 2022-09-09
IN2015DN00694A (en:Method) 2015-06-26
PL2885007T3 (pl) 2019-02-28
NO2022034I1 (no) 2022-08-04
EP3421051B1 (en) 2020-05-13
TW201420115A (zh) 2014-06-01
US20220096619A1 (en) 2022-03-31
PT3421051T (pt) 2020-06-26
HUS2200034I1 (hu) 2022-08-28
US11723965B2 (en) 2023-08-15
JP6291495B2 (ja) 2018-03-14
BR112015003227B1 (pt) 2020-10-27
EP3421051A1 (en) 2019-01-02
CN104661684B (zh) 2018-03-20
MY167579A (en) 2018-09-20

Similar Documents

Publication Publication Date Title
IL237066B (en) Glycoconjugation processes and preparations
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
GB2506426B (en) Composition
GB201200707D0 (en) Composition
EP2878295A4 (en) COMPOSITION
GB201218954D0 (en) Composition
GB2498803B (en) Composition
GB201315350D0 (en) Methods and compositions
GB2508825B (en) Composition
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
GB201315347D0 (en) Methods and compositions
HRP20190326T1 (hr) Pripravak
GB201206035D0 (en) Composition
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
GB201218195D0 (en) Composition
GB201209597D0 (en) Composition
GB201208133D0 (en) Composition
GB201311517D0 (en) Composition
GB201219383D0 (en) Composition
SI2830587T1 (sl) Sestavek za zaščito in uravnoteženje kože
ZA201500493B (en) Glycoconjugation processes and compositions
GB201221334D0 (en) Composition
GB201220838D0 (en) Composition
GB201219065D0 (en) Composition
GB201218334D0 (en) Herbval composition